ATE177785T1 - Mutante des respiratory-syncytial-virus (rs- virus) und eine eine solche mutante enthaltende pharmazeutische zusammensetzung - Google Patents

Mutante des respiratory-syncytial-virus (rs- virus) und eine eine solche mutante enthaltende pharmazeutische zusammensetzung

Info

Publication number
ATE177785T1
ATE177785T1 AT93106496T AT93106496T ATE177785T1 AT E177785 T1 ATE177785 T1 AT E177785T1 AT 93106496 T AT93106496 T AT 93106496T AT 93106496 T AT93106496 T AT 93106496T AT E177785 T1 ATE177785 T1 AT E177785T1
Authority
AT
Austria
Prior art keywords
mutant
virus
pharmaceutical composition
composition containing
respiratory syncytial
Prior art date
Application number
AT93106496T
Other languages
English (en)
Inventor
Valerie Bruce Randolph
Joan Coflan Crowley
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of ATE177785T1 publication Critical patent/ATE177785T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561—Methods of inactivation or attenuation
    • C12N2760/18564—Methods of inactivation or attenuation by serial passage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT93106496T 1992-04-21 1993-04-21 Mutante des respiratory-syncytial-virus (rs- virus) und eine eine solche mutante enthaltende pharmazeutische zusammensetzung ATE177785T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87142092A 1992-04-21 1992-04-21

Publications (1)

Publication Number Publication Date
ATE177785T1 true ATE177785T1 (de) 1999-04-15

Family

ID=25357402

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93106496T ATE177785T1 (de) 1992-04-21 1993-04-21 Mutante des respiratory-syncytial-virus (rs- virus) und eine eine solche mutante enthaltende pharmazeutische zusammensetzung

Country Status (13)

Country Link
US (1) US5932222A (de)
EP (1) EP0567100B1 (de)
JP (1) JPH0622756A (de)
AT (1) ATE177785T1 (de)
AU (1) AU671983B2 (de)
CA (1) CA2094464C (de)
DE (1) DE69323921T2 (de)
DK (1) DK0567100T3 (de)
ES (1) ES2130189T3 (de)
GR (1) GR3029716T3 (de)
NZ (1) NZ247444A (de)
TW (1) TW275632B (de)
ZA (1) ZA932763B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2142817C1 (ru) * 1993-08-06 1999-12-20 Коннот Лабораториз Лимитед Инактивированные вакцины респираторно-синцитиального вируса
DK0784486T3 (da) * 1994-10-05 2006-08-14 Univ Vanderbilt Interleukin-12 som en adjuvans til Paramyxoviridae-vacciner
US6689367B1 (en) * 1995-09-27 2004-02-10 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
US7846455B2 (en) * 1996-07-15 2010-12-07 The United States Of America As Represented By The Department Of Health And Human Services Attenuated chimeric respiratory syncytial virus
US6015664A (en) * 1995-11-03 2000-01-18 Mcw Research Foundation Multiplex PCR assay using unequal primer concentrations to detect HPIV 1,2,3 and RSV A,B and influenza virus A, B
US6077514A (en) * 1996-04-04 2000-06-20 The Regents Of The University Of Michigan Attenuated respiratory syncytial virus
WO1997038138A1 (en) * 1996-04-04 1997-10-16 The Regents Of The University Of Michigan Attenuated respiratory syncytial virus
CA2265554A1 (en) * 1996-09-27 1998-04-02 American Cyanamid Company 3' genomic promoter region and polymerase gene mutations responsible for attenuation in viruses of the order designated mononegavirales
DE19729161A1 (de) 1997-07-08 1999-01-14 Basf Ag Thermisch härtbare, wässrige Zusammensetzungen
KR20010030630A (ko) * 1997-09-19 2001-04-16 윌리암 에이취 캘넌, 에곤 이 버그 약독화 호흡 신시티아 바이러스
CA2323927A1 (en) * 1998-03-26 1999-09-30 American Cyanamid Company Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup b
WO2002012289A2 (en) * 2000-08-07 2002-02-14 Aventis Pasteur Limited Stabilization of immunogens derived from paramyxoviruses
EP1701738B1 (de) * 2003-12-17 2015-03-11 Wyeth LLC Verfahren zur Herstellung von lagerstabilen RSV Zusammensetzungen
GB201202091D0 (en) 2012-02-07 2012-03-21 Renishaw Ireland Ltd Drug delivery apparatus
GB201202093D0 (en) * 2012-02-07 2012-03-21 Renishaw Ireland Ltd Drug storage apparatus
WO2021231767A1 (en) * 2020-05-13 2021-11-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Rsv vaccine bearing one or more p gene mutations
CN112501134B (zh) * 2020-12-09 2023-01-20 贵州医科大学附属医院 一种人呼吸道合胞病毒毒株及其应用
CN113462656B (zh) * 2021-03-24 2022-09-30 兰州生物制品研究所有限责任公司 一种人三型副流感病毒冷适应温度敏感株及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149650A (en) * 1986-01-14 1992-09-22 University Of North Carolina At Chapel Hill Vaccines for human respiratory virus
AU605476B2 (en) * 1986-01-14 1991-01-17 University Of North Carolina, The Vaccines for human respiratory virus
US5223254A (en) * 1987-09-29 1993-06-29 Praxis Biologics, Inc. Respiratory syncytial virus: vaccines
WO1989004835A1 (en) * 1987-11-20 1989-06-01 The Upjohn Company HUMAN RESPIRATORY SYNCYTIALVIRUS VACCINE DERIVED FROM THE 1A (9.5 kD) PROTEIN
MX9203458A (es) * 1987-12-23 1992-09-01 Upjohn Co Segmentos inmunogenicos que contienen glicoproteinas quimericas de las glicoproteinas de virus sincitial respiratorio humano.
IL105456A (en) * 1992-04-21 1996-12-05 American Home Prod Vaccines of attenuated respiratory syncytial virus

Also Published As

Publication number Publication date
ES2130189T3 (es) 1999-07-01
NZ247444A (en) 1994-12-22
DK0567100T3 (da) 1999-09-27
GR3029716T3 (en) 1999-06-30
US5932222A (en) 1999-08-03
EP0567100A1 (de) 1993-10-27
EP0567100B1 (de) 1999-03-17
AU3705793A (en) 1993-10-28
DE69323921T2 (de) 1999-08-26
DE69323921D1 (de) 1999-04-22
CA2094464C (en) 2005-08-23
JPH0622756A (ja) 1994-02-01
ZA932763B (en) 1994-02-08
CA2094464A1 (en) 1993-10-22
TW275632B (de) 1996-05-11
AU671983B2 (en) 1996-09-19

Similar Documents

Publication Publication Date Title
ATE177785T1 (de) Mutante des respiratory-syncytial-virus (rs- virus) und eine eine solche mutante enthaltende pharmazeutische zusammensetzung
EP1712628A3 (de) Verbindungen und Verfahren zur Immuntherapie und Diagnose von Tuberkulose
DE69818707D1 (de) Chitosan und influenza-antigen(e) enthaltende impfstoff-zubereitungen zur verabreichung durch eine mukosa
WO1998053075A3 (en) Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
WO1999042076A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
WO1998016646A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
DE69223914D1 (de) 4-substituierte-2-Deoxy-2,3-Didehydro Alpha-D-Neuraminsäure antivirale Derivate
BR9404831A (pt) Composto,formulação farmacêutica e processo de preparação de um composto
ATE346610T1 (de) Zusammensetzung enthaltend, ein antigen, ein th-1 induzierendes adjuvans und eine im wasser schwer lösliche aminosäure, zur verwendung in der immunisierung
CA2022420A1 (en) Escherichia coli vaccine
DK0404283T3 (da) 11alfa-aryl-4-estrener, fremgangsmåde til fremstilling af disse samt deres anvendelse som lægemidler
DE68921908D1 (de) Zell-assoziierte Glucosyltransferase, Antikörper dagegen und eine diese enthaltende Zusammensetzung zur Prophylaxe von Karies.
DK0764023T3 (da) Forbindelser og præparater til administrering via oral inhalation eller insufflation
ATE153032T1 (de) Zyklische angiopeptin derivate, deren herstellung und pharmazeutische zusammensetzungen
AU653861B2 (en) Respiratory disease vaccine for cats
ATE59290T1 (de) Stabile injizierbare arzneiformulierung des 1,4- dihydroxy-5,8-bis((2-(hydroxyaethylamino)|thyl)amino)anthrachinondihydrochlorids.
DK0418990T3 (da) 13-brom- og 13,14-dibrom-ergoliner, deres fremstilling og anvendelse i lægemidler
CHIN et al. The effect of intraoperative adjustment strabismus surgery under topical anesthesia
ITRM920074A0 (it) Procedimento per la preparazione di vaccini, e vaccini cosi' ottenibili.

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee